VIP943
Near Add Your Location
Accepting patients
VIP943
An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Subjects With Advanced CD123+ Hematologic Malignancies
- Antibody Drug Conjugate (ADC)
- Kinesin Spindle Protein (KSP) Inhibitor
- CD123
- Phase 1